BME 280B Seminar: Artificial intelligence systems to advance engineered T cell immunotherapy designs
Presenter: Zinaida Good, Assistant Professor of Medicine in the Division of Immunology and Rheumatology and the Division of Computational Medicine, Stanford University
Description: T cell immunotherapies have reshaped the treatment landscape for hematologic malignancies and are rapidly extending to solid tumors, autoimmune diseases, and transplant tolerance. Yet durable benefit remains inconsistent, and toxicities remain clinically significant. The current discovery proceeds one edit at a time, and existing preclinical models do not represent patient biology, which often results in failure upon clinical translation. Overcoming these challenges to improve patient outcomes and reduce toxicities requires a systems-level understanding of the multiscale factors governing T cell function and toxicity in patients. Artificial intelligence (AI) approaches offer an exciting opportunity to tackle this problem by learning unified representations from diverse data types spanning molecular, cellular, and clinical modalities. I will provide an overview on our team’s approaches building AI systems that harness primary patient datasets to directly inform advanced T cell designs optimized for clinical outcomes, with validation in preclinical models.
Bio: Zinaida Good, Ph.D., is an Assistant Professor of Medicine in the Division of Immunology and Rheumatology and the Division of Computational Medicine at Stanford University. She also serves as the Director of the Stanford Center for Cancer Cell Therapy Data Hub. The goal of her research program is to understand and enhance engineered T cell immunotherapies for cancer and immune-mediated diseases through innovative computational approaches and systems immunology. Her lab leverages innovation in machine learning and clinical multiomic datasets to build artificial intelligence systems for advanced T cell therapy design. Dr. Good earned her Ph.D. in Computational & Systems Immunology from Stanford University. Her work includes 4 first-author papers (Nature Medicine 2018 & 2022, Nature Biotechnology 2019, Trends in Immunology 2019), 18+ co-authored papers (including Nature 2019, 2022, 2024, Science 2021, Nature Methods 2016, 2022, and NEJM 2024), and an initial senior author papers (ICML 2025, NeurIPS 2025, Frontiers in Immunology 2025). Her research is supported by the NIH/NCI Pathway to Independence Award, NIH/OD Multimodal AI Initiative Award, NIH/NCI Program Project Grant, and the Weill Cancer Hub West. Dr. Good has been named an Arthur & Sandra Irving Cancer Immunology Fellow in 2022, Parker Bridge Fellow in 2023, and an AACR-Woman in Cancer Research Scholar in 2024.
Hosted by: Professor Vanessa Jonsson, BMEbe Department